Skip to content

Qatar Diabetes Mobile Application Trial

Qatar Diabetes Mobile Application Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03998267
Acronym
QDMAT
Enrollment
180
Registered
2019-06-26
Start date
2019-08-22
Completion date
2020-12-31
Last updated
2020-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type2 Diabetes Mellitus

Keywords

mobile health, m-health

Brief summary

Diabetes mobile technology is an emerging and rapidly expanding field that seeks to combine cutting edge behavioral insights with best practice in diabetes self management education to improve patient empowerment and deliver better patient outcomes.The question that arises is whether or not, diabetes mobile applications are effective in improving glycemic control, clinical outcomes, quality of life and overall patient satisfaction, in diabetic patients in Qatar. To answer this, we plan to enroll 90 diabetic patients into a custom-made diabetes app for Qatar (Droobi) (as intervention group) in comparison with 90 diabetic patients followed in the current standard care, matched in characteristics (as control group). We have the hypothesis that with utilization of the mobile application, patients will have improved glycemic control, improved self management and patient empowerment; together with improved patient-educator/doctor interaction.

Interventions

DEVICEDroobi

A new mobile application, specifically built for the diabetes patients in Qatar with the help of local expertise.

OTHERStandard of care

Standard of care including physicians, dietetics and diabetes educators support

Sponsors

Qatar Computing Research Institute (QCRI)
CollaboratorUNKNOWN
Droobi Health
CollaboratorUNKNOWN
Hamad Medical Corporation
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Subjects with T2DM will be randomised into an intervention arm and standard care arm. Subjects in the intervention arm receive usual diabetes care in addition to the mobile app while subjects in the standard care will receive usual diabetes care only.

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* • Adults with T2DM (more than 18 yrs of age and younger than 60) who are able to provide consent * Arabic speaking and non-arabic speaking T2DM patients, who can communicate in Arabic and or English language. * Uncontrolled diabetes with HbA1c more than or equal to 8.5% * T2DM on insulin with or without any other oral medication * Subject must have a smart phone (must be an iOS (Apple) phone user) and must be interested in using a smart phone app. * Subject must have no visual impairment. * Minimal level of literacy (able to read and write in english or arabic). * To be able to communicate via chat with the mobile app team through the app as evidenced by at least weekly use of any of the social media such as WhatsApp, Viber, Facebook Messenger etc * Subject must be willing to utilize a mobile application for diabetes control

Exclusion criteria

* • Recent history (3 months) of stroke or Myocardial infarction. * Patients with proliferating retinopathy * Patients with an acute illness during the past 2 weeks. * Patients who plan to be away for more than 3 months. * Patients with CKD requiring dialysis. * Hypoglycemia unawareness. * More than one episode of severe hypoglycemia in the previous 6 months. * Female patients who are planning for pregnancy in the coming 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Difference in mean HbA1c6 monthsDifference in mean HbA1C between the intervention arm and the standard care

Secondary

MeasureTime frameDescription
Subject perceptions of diabetes self management6 monthsWithin subject changes in perceptions of diabetes self-management as assessed by diabetes self-management questionnaire (DSMQ) scores subsection glucose management and overall rating. DSM-Q is a 16 item questionnaire to assess self-care activities associated with glycemic control. Four subscales, 'Glucose Management' (GM), 'Dietary Control' (DC), 'Physical Activity' (PA), and 'Health-Care Use' (HU), as well as a 'Sum Scale' (SS) as a global measure of self-care. Scale scores are calculated as sums of item scores and then transformed to a scale ranging from 0 to 10 (raw score / theoretical maximum score \* 10. A transformed score of ten thus represents the highest self-rating of the assessed behavior
Change in subjects attitudes towards disease6 monthsWithin subject changes in attitudes towards disease assessed the proportion of subjects with diabetes distress scales (DDS) scores consistent with moderate or high distress.The DDS yields a total distress score plus 4 subscale (emotional burden,physical distress, regimen distress and interpersonal distress) scores each addressing a different kind of distress. A mean item score 2.0-2.9 is considered moderate distress and a mean score of more than or equal to 3 is considered high stress.
Changes in insulin doses6 monthsDifference in number of recommended insulin dose adjustments per subject between intervention and usual care arm
Changes in reported hypoglycemia6 monthsDifference in the number of reported hypoglycemic events per subject between the intervention and usual care arm.
Time to achieve normoglycemia6 monthsReduction in the time required to reach normoglycemia (in-range blood glucose readings) between the intervention and control groups.
Missed clinical appointments6 monthsPercent of missed clinical appointments in each arm.
Weight6 monthsChanges in weight from baseline at 6 months
Blood Pressure6 monthsChanges in blood pressure from baseline at 6 months
Lipids6 monthsChanges in lipids from baseline at 6 months
Number of clinical interactions6 months• Differences in the number of clinical interactions per subjects with healthcare providers through the mobile app and through usual means in the standard care

Other

MeasureTime frameDescription
Exploratory outcome6 monthsIncreased mobile application usability by the system usability scale (SUS) at 6 months. It consists of a 10 item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. The participant's scores for each question are converted to a new number, added together and then multiplied by 2.5 to convert the original scores of 0-40 to 0-100. An SUS score above a 68 would be considered above average and anything below 68 is below average, however the best way to interpret the results involves normalizing the scores to produce a percentile ranking

Countries

Qatar

Contacts

Primary ContactNoor N Suleiman, MD
nsuleiman@hamad.qa+97455816515
Backup ContactDabia H Al Mohanadi
DAlMohanadi@hamad.qa+97455524801

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026